Zanubrutinib is a potent inhibitor of Bruton's tyrosine kinase (BTK) used in the treatment of certain types of cancer. Zanubrutinib impurities are unwanted substances that may be present in the drug product or raw material used to make it. These impurities can potentially affect the safety and efficacy of the drug, and therefore, their identification and control are critical in the drug development process. Common impurities in Zanubrutinib include related compounds, process-related impurities, and degradation products. Their levels must be monitored and controlled to ensure the quality of the drug product.
